Financial News

TRAI Drive Tests in Bikaner Reveal 5G Strength in Urban Areas, Performance Gaps on Highways

India Manufacturing PMI hits four-month high in February but export growth cools

India's Manufacturing PMI rose to 56.9 in February from January's 55.4, but undershot a preliminary estimate of 57.5. A PMI above 50 signals expansion.

West Asia tensions raise risks for trade, oil prices, Indian markets

The West Asia and North Africa region account for about 31% of India’s export-import cargo. If the situation worsens, cargo volumes at Indian ports could decline

Qatar's QNB projects global trade to grow by over 4%

A new global investment cycle centered around AI should favour continues trade growth above the 4% long-term average

USD/INR Shatters Monthly High as Oil Prices Explode Amid US-Iran War Tensions

BitcoinWorldUSD/INR Shatters Monthly High as Oil Prices Explode Amid US-Iran War TensionsThe USD/INR currency pair has surged to a fresh monthly peak, breaking through key resistance levels as escalating military tensions between the United States and Iran trigger a dramatic spike in global oil prices. This development, recorded on trading screens worldwide, reflects the immediate impact of geopolitical instability on emerging market currencies, particularly those of [...]This post USD/INR Shatters Monthly High as Oil Prices Explode Amid US-Iran War Tensions first appeared on BitcoinWorld.

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Stocks master_of_puppetsMon 02/03/2026 - 07:00 FR0000120578 FR0000120578 FR0000120578 02/03/2026 - 07:00 Paris Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Other subject 1001167299-en GlobeNewswire Sanofi Winthrop Industrie Euronext Published 20103015 Pharmaceuticals XPAR BGEM ETLX Language English Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi’s commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, for IgG4-related disease (IgG4-RD). There is still unmet medical need and limited treatment options in Japan for IgG4-RD, a rare, progressive, immune-mediated chronic condition in which the immune system attacks various tissues and organs leading to serious damage. The MHLW grants orphan designation to medicines that address rare diseases or conditions with unmet medical needs. Rilzabrutinib for the treatment of IgG4-RD was evaluated in a phase 2 study (clinical study identifier: https://www.clinicaltrials.gov/study/NCT04520451?term=NCT04520451&rank=...; rel="nofollow" target="_blank">NCT04520451) and results were https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-12-08-...; rel="nofollow" target="_blank">presented at the European Alliance of Associations for Rheumatology 2025 congress. In IgG4-RD patients, treatment with rilzabrutinib for 52 weeks led to reduction in disease flares and other disease markers and minimized the need for treatment with glucocorticoids. The safety profile of rilzabrutinib in the study was consistent with previous studies in other indications, with no new safety signals observed. Treatment-emergent adverse events reported by >10% of patients include diarrhea, COVID-19, dizziness, dry mouth and nausea. Currently, rilzabrutinib in IgG4-RD is being evaluated in the RILIEF phase 3 study (clinical study identifier: https://clinicaltrials.gov/study/NCT07190196" rel="nofollow" target="_blank">NCT07190196). Rilzabrutinib is being studied across multiple rare immune-mediated diseases. In 2025, it received approval for immune thrombocytopenia (ITP) in the US, the EU, and the UAE. Additionally, rilzabrutinib is currently under regulatory review for ITP in Japan. Rilzabrutinib has received several expedited designations from global regulatory authorities for ITP, IgG4-RD, warm autoimmune hemolytic anemia (wAIHA), and sickle cell disease (SCD). Other than the approved ITP indications in the US, EU, and UAE, these uses of rilzabrutinib are investigational and have not been evaluated by any regulatory authority.About rilzabrutinibRilzabrutinib, Wayrilz where approved, is a novel, oral, reversible covalent BTK inhibitor that has the potential to be an effective new medicine for several rare immune-mediated or inflammatory diseases by working to restore immune balance via multi-immune modulation. BTK, expressed in B cells, macrophages, and other innate immune cells, plays a critical role in multiple immune-mediated disease processes and inflammatory pathways. With the application of the TAILORED COVALENCY® technology, rilzabrutinib can selectively inhibit the BTK target. Rilzabrutinib is now approved for the treatment of immune thrombocytopenia (ITP) in the US, the EU, and the UAE. Regulatory review for use in ITP is currently ongoing in Japan. About IgG4-RDIgG4-RD is a progressive, relapsing, chronic immune-mediated rare disease, which can manifest in almost every organ and can lead to organ damage and irreversible dysfunction with a sometimes fatal outcome. People with IgG4-RD experience flare-ups of the condition characterized by periods of exacerbated symptoms. Due to its rarity and challenges with diagnosis, the global prevalence of IgG4-RD is unknown. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | mailto:sandrine.guendoul@sanofi.com" rel="nofollow" target="_blank">sandrine.guendoul@sanofi.comEvan Berland | +1 215 432 0234 | mailto:evan.berland@sanofi.com" rel="nofollow" target="_blank">evan.berland@sanofi.comLéo Le Bourhis | +33 6 75 06 43 81 | mailto:leo.lebourhis@sanofi.com" rel="nofollow" target="_blank">leo.lebourhis@sanofi.comVictor Rouault | +1 617 356 4751 | mailto:victor.rouault@sanofi.com" rel="nofollow" target="_blank">victor.rouault@sanofi.comTimothy Gilbert | +1 516 521 2929 | mailto:timothy.gilbert@sanofi.com" rel="nofollow" target="_blank">timothy.gilbert@sanofi.comLéa Ubaldi | +33 6 30 19 66 46 | mailto:lea.ubaldi@sanofi.com" rel="nofollow" target="_blank">lea.ubaldi@sanofi.comEkaterina Pesheva | +1 410 926 6780 | mailto:ekaterina.pesheva@sanofi.com" rel="nofollow" target="_blank">ekaterina.pesheva@sanofi.com Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | mailto:thomas.larsen@sanofi.com" rel="nofollow" target="_blank">thomas.larsen@sanofi.comAlizé Kaisserian | +33 6 47 04 12 11 | mailto:alize.kaisserian@sanofi.com" rel="nofollow" target="_blank">alize.kaisserian@sanofi.comKeita Browne | +1 781 249 1766 | mailto:keita.browne@sanofi.com" rel="nofollow" target="_blank">keita.browne@sanofi.comNathalie Pham | +33 7 85 93 30 17 | mailto:nathalie.pham@sanofi.com" rel="nofollow" target="_blank">nathalie.pham@sanofi.comNina Goworek | +1 908 569 7086 | mailto:nina.goworek@sanofi.com" rel="nofollow" target="_blank">nina.goworek@sanofi.com Thibaud Châtelet | +33 6 80 80 89 90 | mailto:thibaud.chatelet@sanofi.com" rel="nofollow" target="_blank">thibaud.chatelet@sanofi.comYun Li | +33 6 84 00 90 72 | mailto:yun.li3@sanofi.com" rel="nofollow" target="_blank">yun.li3@sanofi.com Sanofi forward-looking statementsThis press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” "attempt," “target,” “project,” "strategy," "strive," "desire," “predict,” “forecast,” “ambition,” “guideline,” "seek," “should,” “will,” "goal," or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press_Releasehttps://ml-eu.globenewswire.com/Resource/Download/d69126cd-681e-4b38-95...; https://www.globenewswire.com/newsroom/ti?nf=MTAwMTE2NzI5OSM0MDIzNTAxND...; /> https://ml-eu.globenewswire.com/media/YmQ5ZWEzZjctMzFhNS00MzkyLTk4Y2UtN...; referrerpolicy="no-referrer-when-downgrade" /> SANOFI SANOFI 078526 FR0000120578-XPAR FR0000120578-BGEM FR0000120578-ETLX SAN 1SAN 4SAN

Bank of Korea calls for bank-led won stablecoins

Bank of Korea urges limiting won-pegged stablecoins to banks, warning private issuance may threaten monetary policy, spur conflicts, and reshape finance.The post Bank of Korea calls for bank-led won stablecoins appeared first on CoinGeek.

Solvac has taken note of the market reaction following the recent publication of Syensqo’s results and outlook

Press releaseRegulated information

Town Hall redecoration plans submitted with room in 'very poor' condition

Plans have been submitted to redecorate the council chamber of the Town Hall in the Cornhill with Ipswich Borough Council set to make a decision.

Baker defends price of £650 cake after shopper claimed they could 'buy it in Tesco'

A luxury cake designer in Edinburgh has broken down the costs of her bespoke cakes after critics said they were 'too much' and could be bought in Tesco instead

Construction dominates taxable sales increase in Aspen

Construction-related sales more than doubled from 2024 to 2025, contributing to a 10% increase in Aspen’s taxable sales across the board last year.

Major new Nottinghamshire business park could create 1,500 jobs - but plans are 'unwelcome'

Developers say the project could bring in £70 million to the local economy ever year